AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions

Leukemia

Volumn 24, Issue 5, 2010, Pages 1065-1069

  Haferlach, C ^a   Dicker, F ^a   Kohlmann, A ^a   Schindela, S ^a   Weiss, T ^a   Kern, W ^a   Schnittger, S ^a   Haferlach, T ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; CD135 ANTIGEN; CONTRACTILE PROTEIN; CORE BINDING FACTOR BETA; JANUS KINASE 2; K RAS PROTEIN; MYOSIN HEAVY CHAIN 11; NEUROFIBROMIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME ABERRATION; CHROMOSOME BANDING PATTERN; CLINICAL ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; HETEROZYGOSITY LOSS; HUMAN; LETTER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77952420655     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.22     Document Type: Letter

References (8)

1. Castilla LH, Perrat P, Martinez NJ, Landrette SF, Keys R, Oikemus S et al. Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. Proc Natl Acad Sci USA 2004; 101: 4924-4929.
2. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107: 3847-3853.
3. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904-3911. (Pubitemid 46630738)
4. Abbas S, Rotmans G, Lowenberg B, Valk PJ. Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias. Haematologica 2008; 93: 1595-1597.
5. Cutts BA, Sjogren AK, Andersson KM, Wahlstrom AM, Karlsson C, Swolin B et al. Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice. Blood 2009; 114: 3629-3632.
6. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002; 39: 6-11.
7. Bullinger L, Rucker FG, Kurz S, Du J, Scholl C, Sander S et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007; 110: 1291-1300.
8. Neubauer A, Maharry K, Mrozek K, Thiede C, Marcucci G, Paschka P et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 2008; 26: 4603-4609.